Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
AbbVie's (ABBV) Skyrizi Meets Ulcerative Colitis Study Goals
09:20am, Friday, 16'th Jun 2023
AbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical remission in a late-stage study as a maintenance treatment for ulcerative colitis.
This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy?
08:30am, Friday, 16'th Jun 2023
Coherus Biosciences will soon likely commercialize a generic copy of Humira. Humira is AbbVie's largest-grossing drug, and one of the most lucrative of all time.
Roche's cancer therapy gets US FDA nod, heating up competition with AbbVie
07:28am, Friday, 16'th Jun 2023
The U.S. Food and Drug Administration (FDA) greenlighted Roche Holding AG's experimental therapy to treat a type of advanced blood cancer, nearly a month after the approval of a rival therapy from Abb
BeiGene shares drop after AbbVie unit files patent-infringement lawsuit over cancer drug
08:30am, Thursday, 15'th Jun 2023
BeiGene Ltd.'s ADR BGNE was down more than 7% premarket on Thursday after AbbVie's ABBV Pharmacyclics unit filed a patent-infringement lawsuit against the biotech company.
Abbvie, Coherus agree to resolve dispute over Humira biosimilar
07:10am, Thursday, 15'th Jun 2023
Coherus BioSciences Inc said on Thursday it had agreed to resolve a dispute over its plans to launch a lower-priced version of AbbVie Inc's Humira, its blockbuster rheumatoid arthritis drug.
My Dividend Stock Portfolio: New All-Time Dividend Record - 99 Holdings With 25 Buys
09:10am, Wednesday, 14'th Jun 2023
US stocks ended May with solid gains and extended their strong performance into June, boosted by positive labor market data and the debt ceiling bill's progress. My investment activity in May picked u
Nicholas Ward's Dividend Growth Portfolio: April And May Review
07:50am, Tuesday, 13'th Jun 2023
My passive income stream increased by 25.59% YoY in April 2023 and 40.02% YoY in May 2023, with a year-to-date growth of 29.99%. I have been taking advantage of high yields on money market funds and s
Final Trades: Abbvie, Broadcom, Deere
02:40pm, Monday, 12'th Jun 2023
The "Halftime Report" traders give their top picks to watch for the second half.
7 Top Blue-Chip Stocks to Buy in June 2023
04:25pm, Sunday, 11'th Jun 2023
The market probably feels like the movie Groundhog's Day for many investors. The major indexes continue to trade within a range, which is frustrating both bulls and bears.
Better Long-Term Buy: AbbVie or Novo Nordisk?
08:05am, Saturday, 10'th Jun 2023
Novo Nordisk is forecasting revenue and operating profit growth this year. AbbVie said it expects to return to revenue growth in 2025.
4 Factor Dividend Growth Portfolio - Passively Outpacing The Market
05:39pm, Friday, 09'th Jun 2023
The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF™, with a few minor twists. The portfolio gained 1.84% in May, outpe
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
10:12am, Friday, 09'th Jun 2023
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
NY AG approves $17.3 billion opioid settlement with CVS, Walgreens, Teva and AbbVie's Allergan
10:09am, Friday, 09'th Jun 2023
New York Attorney General Letitia James announced Friday the final approval of $17.3 billion in national settlement agreements with drug-store chains CVS Health Corp. CVS, and Walgreens Boots Alliance
4 Dividend Aristocrat Buys For June And 5 To Watch
06:59pm, Thursday, 08'th Jun 2023
"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com/Investing. 67 Aristocrats, screened as of June 6, 2023, repre
Is AbbVie or Amgen the Better Bargain Buy Right Now?
12:15pm, Thursday, 08'th Jun 2023
Exclusivity losses can be big setbacks for pharma companies. AbbVie and Amgen both face this key overhang.
